Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trappsol Cyclo in early Alzheimer's disease
2022-003819-29Phase 2Terminated
- Sponsor
- Cyclo Therapeutics, Inc.
- Start
- Dec 2022
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Trappsol Cyclo with Placebo (2 arms). Primary endpoint: Safety endpoints. Started Dec 2022; status: terminated.
02
Drugs
Trappsol Cyclo
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-003819-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003819-29.